Abstract
Among the candidate anti-prion chemotherapeutic agents identified to date, complex polyamines constitute the only class of compounds that possess the ability to remove pre-existing PrPSc molecules from infected cells. The potency of branched polyamines such as cationic dendrimers increases with the density of positive charges on their surface. Cationic dendrimers appear to accumulate together with PrPSc molecules in lysosomes, where the acidic environment facilitates dendrimer-mediated PrPSc disaggregation. Dendrimers can disaggregate a range of different amyloid proteins by interacting with specific epitopes on each protein. Studies with model peptides suggest that dendrimers may cause fiber breakage and capping of elongating fibers. Potential limitations to the development of dendrimers as therapeutic compounds for neurodegenerative disorders of protein misfolding such as prion diseases include poor bioavailability, limited spectrum of activity, and detrimental neurological side effects. A related group of compounds, lipopolyamines, are smaller molecules containing a lipophilic tail that may assist membrane targeting. Developing strategies to enable the safe delivery of potent complex polyamines to the central nervous system represents a critical avenue for future research.
Keywords: Prion, PrPSc, branched polyamines, dendrimers
CNS & Neurological Disorders - Drug Targets
Title: Complex Polyamines: Unique Prion Disaggregating Compounds
Volume: 8 Issue: 5
Author(s): Surachai Supattapone, Justin R. Piro and Judy R. Rees
Affiliation:
Keywords: Prion, PrPSc, branched polyamines, dendrimers
Abstract: Among the candidate anti-prion chemotherapeutic agents identified to date, complex polyamines constitute the only class of compounds that possess the ability to remove pre-existing PrPSc molecules from infected cells. The potency of branched polyamines such as cationic dendrimers increases with the density of positive charges on their surface. Cationic dendrimers appear to accumulate together with PrPSc molecules in lysosomes, where the acidic environment facilitates dendrimer-mediated PrPSc disaggregation. Dendrimers can disaggregate a range of different amyloid proteins by interacting with specific epitopes on each protein. Studies with model peptides suggest that dendrimers may cause fiber breakage and capping of elongating fibers. Potential limitations to the development of dendrimers as therapeutic compounds for neurodegenerative disorders of protein misfolding such as prion diseases include poor bioavailability, limited spectrum of activity, and detrimental neurological side effects. A related group of compounds, lipopolyamines, are smaller molecules containing a lipophilic tail that may assist membrane targeting. Developing strategies to enable the safe delivery of potent complex polyamines to the central nervous system represents a critical avenue for future research.
Export Options
About this article
Cite this article as:
Supattapone Surachai, Piro R. Justin and Rees R. Judy, Complex Polyamines: Unique Prion Disaggregating Compounds, CNS & Neurological Disorders - Drug Targets 2009; 8 (5) . https://dx.doi.org/10.2174/187152709789541952
DOI https://dx.doi.org/10.2174/187152709789541952 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
NGS Technologies as a Turning Point in Rare Disease Research , Diagnosis and Treatment
Current Medicinal Chemistry Hybrid-Based Multi-Target Ligands for the Treatment of Alzheimer's Disease
Current Topics in Medicinal Chemistry Editorial :
Recent Patents on CNS Drug Discovery (Discontinued) Ethanolamine: A Potential Promoiety with Additional Effects on the Brain
CNS & Neurological Disorders - Drug Targets Matter of Life and Death: the Pharmacological Approaches Targeting Apoptosis in Brain Diseases
Current Pharmaceutical Design TARDBP Ala382Thr Mutation in Multiple Sclerosis: A Possible Role in Brain Atrophy
Current Medical Imaging The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Brain: The Potential Diagnostic and Therapeutic Target for Glaucoma
CNS & Neurological Disorders - Drug Targets Ubiquitin-Proteasome Pathway Components as Therapeutic Targets for CNS Maladies
Current Pharmaceutical Design Alzheimer’s Disease-like Early-phase Brain Pathogenesis: Self-curing Amelioration of Neurodegeneration from Pro-inflammatory ‘Wounding’ to Anti-inflammatory ‘Healing’
Current Alzheimer Research Recent Updates in the Alzheimer’s Disease Etiopathology and Possible Treatment Approaches: A Narrative Review of Current Clinical Trials
Current Molecular Pharmacology Sertraline Associated with REM Sleep Behavior Disorder: A Case Report
Current Psychopharmacology Immunoregulatory Impact of Food Antioxidants
Current Pharmaceutical Design Editorial: New Avenues and Therapeutic Strategies for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Nanoparticles as Alternative Strategies for Drug Delivery to the Alzheimer Brain: Electron Microscopy Ultrastructural Analysis
CNS & Neurological Disorders - Drug Targets Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 Alpha: An Emerging Target for Neuroprotection in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Dihydroartemisinin Ameliorates Decreased Neuroplasticity-Associated Proteins and Excessive Neuronal Apoptosis in APP/PS1 Mice
Current Alzheimer Research Heat Shock Proteins and Proteasome Function in Neurodegeneration
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Commentary: Hot, Hotter, and Hottest Trends in α-Synuclein Research
Current Protein & Peptide Science